CEO | Page 17 of 21 | SpiritIndia.com

Influenza :: Novartis receives US government contract to develop a novel antigen technology

Novartis announced that it has received a contract from the US Department of Health and Human Services (HHS) of approximately USD 55 million. The contract supports the company’s efforts to bring the antigen-sparing capabilities of the MF59 adjuvant to the United States. An adjuvant is a substance added to a vaccine to enhance the body’s immune response to the vaccine’s active constituent, called the antigen.

Health Insurance :: PhRMA expands efforts to help uninsured – Health Insurance

The Pharmaceutical Research and Manufacturers of America, through its Partnership for Prescription Assistance (PPA), is expanding its educational efforts today aimed at making uninsured Americans aware of programs that are available to help them better afford their prescription medicines and finding healthcare services in their community.

Multiple Myeloma :: New treatment options for multiple myeloma

KATHY GIUSTI is the founder and CEO of the MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF). The death of actor Peter Boyle has encouraged additional national interest in the potentially fatal disease known as multiple myeloma.

Malaria :: PATH Malaria Vaccine Initiative, Sanaria to develop novel malaria vaccine

In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

HIV :: International AIDS Vaccine Initiative (IAVI) statement on male circumcision

The International AIDS Vaccine Initiative (IAVI) issued this statement today following a National Institutes of Health (NIH) decision to end two clinical trials of adult male circumcision in Uganda and Kenya. The NIH’s Data Safety and Monitoring Board (DSMB), reviewing interim data, found that medically performed circumcision significantly protected men in the trial from HIV infection.

Hepatitis :: Abbott, Enanta to Develop and Commercialize HCV Protease Inhibitors

Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide agreement to develop and commercialize hepatitis C virus (HCV) NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated attractive efficacy and pharmacokinetic profiles in pre-clinical studies.

Robotics, laser and wireless technologies make driving safer for wheelchair users

The Automatic Transport and Retrieval System, developed with help from engineers at Lehigh and Carnegie Mellon universities, also allows wheelchair users to drive without reconfiguring their vehicles. It will go on sale next spring.

Thrombocytopenia :: Positive clinical trial results of investigational thrombocytopenia agent

At the American Society of Hematology meeting in Orlando AkaRx, Inc. presented the positive results from two Phase I studies of AKR-501, an investigational compound for the treatment of thrombocytopenia.

Immunity :: Researchers in Montreal and the US create model of key immune-system component

Researchers at Universit? de Montr?al, working with teams at Massachusetts General Hospital and Johns Hopkins University, have made a major breakthrough in understanding an essential aspect of the immune system.

Medicare :: Education and Outreach For Medicare Part D

My Medicare Matters TM, which is sponsored by the National Council on Aging (NCOA) and supported through a grant from AstraZeneca Pharmaceuticals LP (NYSE: AZN), announced today its targeted community-based education and outreach initiatives in 2007 in support of Medicare Part-D, which will include a project designed to identify and pilot innovative strategies that can help find and reach low-income seniors who may be eligible for Medicare Extra Help and other prescription savings programs.